D.J. Covell, M.C. White / Tetrahedron 69 (2013) 7771e7778
7775
This material was then subjected to the standard procedure for
cleavage of the allylic acetate, which afforded allylic alcohol (ꢁ)-9
ready for subsequent resolution: Run 1: 188 mg, 0.877 mmol, 96%
yield; [B/L]¼5.1:1. Run 2: 179 mg, 0.835 mmol, 95% yield; [B/L]¼
4.3:1. Run 3 (gram scale): 879 mg, 4.101 mmol, 96% yield; [B/L]¼
4.1:1.
CDCl3) d 173.2, 170.2, 136.0, 133.0, 128.5, 128.0, 126.7, 126.6, 73.7,
51.7, 29.8, 29.5, 21.2; IR (neat, cmꢀ1) 3085.6, 3025.8, 2952.5,
2848.4,v1737.6, 1658.5, 1598.7, 1597.4, 1494.6; HRMS (ESI) m/z cal-
culated for C15H18O4Na [MþNa]þ: 285.1103; found 285.1092.
4.2.3. General procedure for resolution with Novozyme 435. To
a flame dried round bottom flask containing allylic alcohol to be re-
solved (1 equiv) were added vinyl acetate (0.6 M) and Novozyme 435
immobilized on polystyrene beads (33.3 mg/1 mmol). The reaction
mixture was stirred vigorously at room temperature for 36 h. Upon
completion, the solid supported enzyme was removed via filtration.
The solid support was rinsed thoroughly with diethyl ether and then
the filtrate reduced in vacuo and purified via standard SiO2 chroma-
tography. Enantioselectivities were determined by chiral gas chro-
matographic analysis on the acetylated derivative of each isolated
alcohol. It was found that the recovered solid supported enzyme
could be used up to five times with little diminishment in activity.
Individual yields and selectivities are reported below.
4.2.2.3. 2-((3R)-Pent-3-acetoxy-4-en-1-yl-3-ol)-1,3-dioxane 13-
OAc. Following the general procedure for the asymmetric branched
allylic CeH oxidation afforded: Run 1: 180 mg, 0.840 mmol, 84%
yield; [B/L]¼4.8:1:1, [ee]¼44%. Run 2: 178 mg, 0.831 mmol, 83%
yield; [B/L]¼4.3:1, [ee]¼46% (
b
-cyclodextrin, 110 ꢂC isothermal,
tR(R)¼22.21 min, tR(S)¼22.79 min) [average yield: 84%]. This ma-
terial was taken forward without further purification. 1H NMR
(500 MHz, CDCl3)
d
5.76 (ddd, J¼6.5, 10.5, 17.3 Hz, 1H), 5.24 (q,
J¼6.5 Hz, 1H), 5.23 (dm, J¼17.5 Hz, 1H), 5.16 (dm, J¼10.5 Hz, 1H),
4.53 (t, J¼5.0 Hz, 1H), 4.09 (m, 2H), 3.75 (dt, J¼3.0, 12.5 Hz, 2H),
2.12e2.02 (m, 1H), 2.06 (s, 3H), 1.78e1.58 (m, 4H), 1.33 (dm,
J¼13.5 Hz, 1H); 13C NMR (125 MHz, CDCl3)
d 170.2, 136.3, 116.7,
101.7, 74.3, 66.9, 30.7, 28.5, 25.8, 21.1; IR (neat, cmꢀ1) 3087.5, 2962.1,
2931.3, 2852.2, 2780.9, 2732.7, 2661.3, 1739.5, 1646.9, 1430.9,
1407.8; HRMS (ESI) m/z calculated for C11H18O4Na [MþNa]þ:
237.1103; found 237.1104.
4.2.3.1. (ꢀ)-(4R)-1-O-Benzyl-5-hexen-1,4-diol (ꢀ)-3. Following
the general procedure for Novozyme 435 resolution afforded: Run
1: 105 mg, 0.509 mmol, 57% yield; [B/L]¼>20:1, [ee]¼98%. Run 2:
100 mg, 0.485 mmol, 55% yield; [B/L]¼>20:1, [ee]¼99%. Enantio-
meric excess was determined on the acylated derivative of the final
This material was then subjected to the standard procedure for
cleavage of the allylic acetate, which afforded allylic alcohol (ꢁ)-13
ready for subsequent resolution: Run 1: 141 mg, 0.819 mmol, 97%
yield; [B/L]¼4.8:1. Run 2: 135 mg, 0.784 mmol, 94% yield; [B/L]¼
4.3:1.
product (ee determined on the acylated alcohol,
b-cyclodextrin,
120 ꢂC isothermal, tR(R)¼65.56 min, tR(S)¼67.14 min) [average
yield: 56%]. [
d
a
]
ꢀ2.86 (c 2.0, CHCl3). 1H NMR (500 MHz, CDCl3)
26
D
7.37e7.32 (m, 4H), 7.30e7.25 (m, 1H), 5.87 (ddd, J¼17.0, 10.5,
6.0 Hz, 1H), 5.25 (dt, J¼17.0, 1.5 Hz, 1H), 5.10 (dt, J¼10.5, 1.5 Hz, 1H),
4.52 (s, 2H), 4.13 (m, 1H), 3.52 (t, J¼6.0 Hz, 2H), 2.27 (d, J¼4.5 Hz,
4.2.2.4. (4R,E)-Methyl 4-acetoxy-6-phenylhex-5-enoate (18). The
general procedure for the asymmetric branched allylic CeH oxi-
dation was modified in the following way to generate allylic acetate
(18). A round bottom flask (25 mL) was charged with the following:
1,2-bis(phenylsulfinyl)ethane palladium(II) acetate (1) (10 mol %,
0.50 mmol, 250 mg); (1R,2R)-(ꢀ)-[1,2-cyclohexanediamino-N,N0-
bis(3,5-di-tert-butylsalicylidene)]chromium(III)F (R,R-2) (10 mol %,
0.50 mmol, 308 mg), 1,4-benzoquinone (2 equiv, 10.0 mmol, 1.08 g),
2H), 1.77e1.57 (m, 4H); 13C NMR (125 MHz, CDCl3)
d 141.0, 138.1,
128.3, 127.6, 127.6, 114.4, 72.9, 72.6, 70.2, 34.2, 25.7; IR (neat, cmꢀ1
)
3403.8, 3066.3, 3031.6, 2979.5, 2942.9, 2858.0, 2798.2, 1643.1.0,
1496.5, 1454.1; HRMS (ESI) m/z calculated for C13H18O2Na
[MþNa]þ: 229.1204; found: 229.1204.
4.2.3.2. Methyl (9R)-9-hydroxyundec-10-eneoate (ꢀ)-9. Follow-
ing the general procedure for Novozyme 435 resolution afforded:
Run 1: 119 mg, 0.555 mmol, 63% yield; [B/L]¼>20:1, [ee]¼99%. Run
2: 109 mg, 0.509 mmol, 61% yield; [B/L]¼>20:1, [ee]¼98%, Run 3
(gram scale): 523 mg, 2.441 mmol, 60% yield; [B/L]¼>20:1, [ee]¼
Ó
ꢀ
an activated 4 A MS bead (w30 mg), and a Teflon stir bar. A sep-
arate vial (2 mL, borosilicate) was charged with the following:
methyl hexenoate (1.0 equiv, 5.0 mmol, 0.704 mL), AcOH (1.1 equiv,
5.5 mmol, 0.315 mL), and EtOAc (0.50 mL). The liquids were
transferred to the solids via pipette and the vial rinsed with EtOAc
(4ꢃ0.50 mL). After carefully stirring for 48 h at room temperature,
to the reaction mixture were added phenyl boronic acid (1.5 equiv,
7.5 mmol, 0.914 g), AcOH (1 equiv, 5 mmol, 0.285 mL), and EtOAc
(12.5 mL). The reaction mixture was stirred at room temperature
until complete by TLC (w4 h) at which point the reaction mixture
was transferred to a separatory funnel with w5 mL EtOAc and di-
luted with hexanes (400 mL). The organic layer was rinsed with
satd aq NaHSO3 (1ꢃ50 mL) and 5% aq K2CO3 (2ꢃ50 mL). Caution
should be taken when combining aqueous layers as carbon dioxide is
evolved. The combined aqueous layers were back extracted with
hexanes (100 mL). The combined organic layers were dried
(MgSO4), filtered, and reduced in vacuo. The resulting oil was re-
dissolved in hexanes (150 mL) and extracted again with 5%
aq K2CO3 (3ꢃ25 mL) to remove residual hydroquinone. The organic
layer was again dried (MgSO4), filtered, and reduced in vacuo This
product was generally taken forward without further purification,
but was isolated and purified via silica gel chromatography for
characterization. [B/L]¼>20:1, [ee]¼50% (determined on the initial
99% (ee determined on the acylated alcohol,
b
-cyclodextrin, 120 ꢂC
25
isothermal, tR(R)¼55.92 min) [average yield: 62%]. [
a
]
ꢀ5.13 (c
D
1.0, CHCl3). 1H NMR (500 MHz, CDCl3)
d
5.86 (ddd, J¼16.9, 10.8,
6.0 Hz, 1H), 5.22 (d, J¼17.0 Hz, 1H), 5.10 (d, J¼10.5 Hz, 1H), 4.09 (p,
J¼5.5 Hz, 1H), 3.66 (s, 3H), 2.30 (t, J¼7.5 Hz, 2H),1.63e1.30 (m, 13H);
13C NMR (125 MHz, CDCl3)
d 174.2, 141.3, 114.4, 73.2, 51.4, 37.0, 34.1,
29.3, 29.1, 29.0, 25.2, 24.9; IR (neat, cmꢀ1) 3426.9, 2979.5, 2931.3,
2856.1, 1739.5, 1436.7; HRMS (ESI) m/z calculated for C12H22O3Na
[MþNa]þ: 237.1467; found: 237.1471.
4.2.3.3. 2-((3R)-Pent-4-en-1-yl-3-ol)-1,3-dioxane (ꢀ)-13. Follow
ing the general procedure for Novozyme 435 resolution afforded:
Run 1: 80 mg, 0.464 mmol, 57% yield; [B/L]¼>20:1:1, [ee]¼99%.
Run 2: 76 mg, 0.441 mmol, 56% yield; [B/L]¼>20:1, [ee]¼99% (ee
determined on the acylated alcohol,
b
-cyclodextrin, 110 ꢂC iso-
thermal, tR(R)¼22.31 min, tR(minor)¼22.93 min) [average yield:
24
57%]; [
a
]
D
ꢀ5.01 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3)
d 5.86
(ddd, J¼5.6, 10.4, 17.3 Hz, 1H), 5.24 (dt, J¼1.6, 17.2 Hz, 1H), 5.10 (dt,
J¼1.2, 10.8 Hz, 1H), 4.58 (t, J¼4.4 Hz, 1H), 4.18e4.08 (m, 3H), 3.77
(app t, J¼11.6 Hz, 2H), 2.36 (d, J¼4.0 Hz, 1H), 2.08 (qt, J¼4.0, 12.4,
1H), 1.78e1.58 (m, 4H), 1.35 (d sep, J¼1.2, 13.6 Hz, 1H); 13C NMR
branched acetate product prior to oxidative Heck reaction, b-cy-
clodextrin, 110 ꢂC isothermal, tR(R)¼5.52 min, tR(S)¼5.83 min). 1H
NMR (500 MHz, CDCl3)
d
7.39 (d, J¼7.5 Hz, 2H), 7.34 (t, J¼7.5 Hz,
(125 MHz, CDCl3) d 141.0, 114.4, 102.1, 72.6, 66.9, 31.2, 31.1, 25.7; IR
2H), 7.31e7.25 (m, 1H), 6.64 (d, J¼16.0 Hz, 1H), 6.12 (dd, J¼7.5,
15.8 Hz, 1H), 5.46 (q, J¼6.5 Hz, 1H), 3.68 (s, 3H), 2.42 (dt, J¼2.0,
7.8 Hz, 2H), 2.13e2.07 (m, 2H), 2.10 (s, 3H); 13C NMR (125 MHz,
(neat, cmꢀ1) 3430.8, 3079.8, 2962.1, 2929.4, 2856.1, 2734.6, 1643.1,
1429.0, 1405.9; HRMS (ESI) m/z calculated for C9H16O3Na [MþNa]þ:
195.0995; found 195.0997.